4月2日,港股四环医药(00460)发布公告,本集团旗下渼颜空间自主研发的注射用聚己内酯微球面部填充剂获得中国国家药品监督管理局批准。该产品市场简称“少女针”,具有即刻填充效果和长期持续刺激的特点,单次治疗效果通常持续超过1年。四环医药宣告这一成果是公司“医美+创新药”战略的又一里程碑。不过,四环医药近日发布的2024财年年报,却让投资者大失所谓。公司在2024年1月1日-2024年12月31日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.